bioMerieux (BMXMF)
(Delayed Data from OTC)
$120.08 USD
-2.42 (-1.98%)
Updated Sep 23, 2024 02:14 PM ET
3-Hold of 5 3
C Value B Growth F Momentum C VGM
Income Statements
Fiscal Year end for bioMerieux falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 3,977 | 3,781 | 3,994 | 3,562 | 2,996 |
Cost Of Goods | 1,751 | 1,665 | 1,671 | 1,559 | 1,353 |
Gross Profit | 2,227 | 2,116 | 2,323 | 2,003 | 1,643 |
Selling & Adminstrative & Depr. & Amort Expenses | 1,751 | 1,498 | 1,396 | 1,372 | 1,228 |
Income After Depreciation & Amortization | 475 | 619 | 928 | 631 | 415 |
Non-Operating Income | -3 | 9 | -3 | -4 | -3 |
Interest Expense | -2 | 2 | 8 | 29 | 23 |
Pretax Income | 473 | 626 | 916 | 599 | 389 |
Income Taxes | 124 | 148 | 208 | 139 | 87 |
Minority Interest | -38 | -12 | -3 | -2 | -3 |
Investment Gains/Losses | 0 | 0 | -1 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | 349 | 478 | 708 | 460 | 302 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | 387 | 477 | 711 | 462 | 306 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 712 | 840 | 1,201 | 872 | 627 |
Depreciation & Amortization (Cash Flow) | 236 | 221 | 273 | 241 | 212 |
Income After Depreciation & Amortization | 475 | 619 | 928 | 631 | 415 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 118.80 | 118.43 | 118.80 | 118.59 | 118.61 |
Diluted EPS Before Non-Recurring Items | 3.26 | 4.02 | 5.99 | 3.90 | 2.58 |
Diluted Net EPS (GAAP) | 3.26 | 4.02 | 5.99 | 3.90 | 2.58 |
Fiscal Year end for bioMerieux falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | NA | NA | NA | NA | NA |
Cost Of Goods | NA | NA | NA | NA | NA |
Gross Profit | NA | NA | NA | NA | NA |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Non-Operating Income | NA | NA | NA | NA | NA |
Interest Expense | NA | NA | NA | NA | NA |
Pretax Income | NA | NA | NA | NA | NA |
Income Taxes | NA | NA | NA | NA | NA |
Minority Interest | NA | NA | NA | NA | NA |
Investment Gains/Losses | NA | NA | NA | NA | NA |
Other Income/Charges | NA | NA | NA | NA | NA |
Income From Cont. Operations | NA | NA | NA | NA | NA |
Extras & Discontinued Operations | NA | NA | NA | NA | NA |
Net Income (GAAP) | NA | NA | NA | NA | NA |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | NA | NA | NA | NA | NA |
Diluted EPS Before Non-Recurring Items | NA | NA | NA | NA | NA |
Diluted Net EPS (GAAP) | NA | NA | NA | NA | NA |